Aspira Women’s Health has partnered with the Dana-Farber Cancer Institute to develop a noninvasive miRNA-based test for identifying ovarian cancer in women with adnexal masses.
This test combines circulating microRNAs with proteins or other factors to improve diagnostic accuracy. The integration of this noninvasive test into Aspira’s ovarian cancer risk assessment portfolio aims to provide physicians with valuable information for determining appropriate treatment pathways. This development has the potential to revolutionize ovarian cancer diagnostics and improve patient outcomes.
Belong.Life has introduced an AI oncology mentor called Dave, which offers personalized information and support for cancer patients and their families. Dave is trained on patient-physician and patient-to-patient interactions, retaining a long-term memory of previous conversations. This allows for continuous communication and enhances the quality of care. Belong.Life offers Dave as a free feature within their Beating Cancer Together app, as well as a customizable software-as-a-service (SaaS) solution for hospitals, providers, and patient support programs. This allows them to incorporate in-house clinical guidelines for optimal utilization.
These advancements in healthcare technology driven by AI have the potential to revolutionize provider operations, diagnostics, and patient engagement. These innovations promise to significantly enhance patient outcomes and transform the healthcare industry worldwide by improving efficiency, reducing administrative burdens, and delivering personalized care.
Read more here: https://lnkd.in/eEQHQat8